🧾 What This Document Is

This is a 6-K filing from Galapagos NV, a Belgian biotech company. It's a "current report" filed with the SEC to inform investors of major events. This specific filing announces that Galapagos has published its 2025 Annual Report and is calling two shareholder meetings for April 28, 2026. Think of it as a combined news release and official notice for investors.

🏢 What The Company Does

👉 In simple terms, Galapagos is a biotech company that acts like a "deal-maker" for drug programs. Instead of discovering all its own medicines from scratch, it uses its expertise and cash to find, buy, and advance promising drug candidates from others, focusing on cancer and immune diseases. The company is now undergoing a massive strategic shift, exiting its own cell therapy research to focus entirely on this deal-making model.

💰 Financial Highlights (2025)

The year 2025 was a tale of two stories: a big accounting profit driven by a past deal, and the high costs of shutting down its old strategy.

• Total Revenue: €1.11 billion (up from €276 million in 2024). This huge jump was mainly from recognizing the remaining €1.07 billion in deferred income from its old drug discovery platform deal with Gilead. This is an accounting move, not new cash coming in.
• Net Profit: €321 million profit (compared to €74 million in 2024). Again, this is heavily influenced by the one-time revenue recognition and tax benefits from writing down assets.
• R&D Expenses: €459 million (up from €335 million). Costs rose due to severance and other charges from winding down cell therapy and restructuring the small molecule business.
• Cash is King: The company ended 2025 with a war chest of €3.0 billion in cash and investments (€87.9M cash + €2.91B financial investments). This is the fuel for its new strategy.

Why it matters: The profit is not from core operations. The key number is the €3.0 billion war chest, which gives Galapagos significant firepower to acquire new drug programs without needing to raise money soon.

🚀 The Big Strategic Pivot

This is the core story. Galapagos is completely reinventing itself.

• Exiting Cell Therapy: After a failed attempt to sell its cell therapy unit, the company decided to wind it down entirely. This involves closing labs in the Netherlands, Switzerland, the U.S., and China, and cutting ~365 jobs.
• New "Deal-Maker" Focus: The company will now use its cash and partnership with Gilead to license or acquire clinically-tested drugs in oncology and immunology. It wants to be a lean, fast-moving organization.
• Proposed Name Change: To signal this fresh start, the board proposes changing the company's name from Galapagos NV to Lakefront Biotherapeutics NV.

Why it matters: This is a high-stakes transformation. The company is betting its future on its management's ability to find and close smart deals with its €3 billion, rather than on its own R&D labs.

📦 Upcoming Shareholder Votes (April 28, 2026)

Two meetings are back-to-back, where shareholders will decide the company's future.

• Annual Meeting (AGM): Focuses on appointing the new leadership team, including CEO Henry Gosebruch and several new independent directors.
• Extraordinary Meeting (EGM): Votes on the critical strategic moves:
  1. Approving the name change to Lakefront Biotherapeutics.
  2. Authorizing the repurchase of up to 10% of its shares.
  3. Renewing the board's authority to issue new shares.

Why it matters: Shareholders are being asked to formally approve the entire new direction—the new board, the new name, and the financial tools to execute the strategy.

🔮 What's Next (2026 Guidance)

The company provided clear financial expectations as it transitions.

• Cash Costs: Expects €125-175 million in one-time restructuring costs in 2026 to complete the wind-down.
• Pipeline Costs: Plans to spend up to €40 million to complete the Phase 2 trials for its remaining drug candidate, GLPG3667 (for autoimmune diseases).
• Cash Flow Goal: Aims to be cash flow neutral to positive by the end of 2026, excluding any new deals or currency swings.
• Ending Cash: Expects to have €2.775 - €2.850 billion in cash and investments at the end of 2026.

Why it matters: These numbers show the "burn rate" to shut down the old business and the remaining pipeline. The goal to reach cash flow breakeven shows a path to sustainability while they hunt for new deals.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Massive Financial Firepower: €3 billion provides runway and negotiating power.
• Experienced New Deal-Making Team: The new C-suite has extensive M&A and business development experience.
• Strategic Partnership with Gilead: Gilead is a major shareholder (>25%) and a potential partner for future deals.

⚠️ Key Risks:

• Execution Risk: The entire strategy hinges on management's ability to find and close good deals. No guarantees.
• "Blank Check" Risk: Investors are essentially trusting the team to deploy capital wisely; there's no existing pipeline to show for it yet.
• Transition Period: The company is shrinking to ~35-40 employees, which is a radical change in scale and capability.

🧠 The Analogy

Galapagos is like a special forces team that has been given a large endowment after completing its last mission. It has disbanded its old specialized units (cell therapy), kept its core leadership of expert strategists, and is now using its funds to identify, acquire, and deploy the best external "talent" (drug programs) to win new, high-stakes battles (in oncology and immunology).

📇 Key Contacts & People

• Investor Relations & Media: Sherri Spear
• Phone: +1 412 522 6418
• Email: [email protected]
• CEO: Henry Gosebruch
• Chair of the Board: Jérôme Contamine

🧩 Final Takeaway

This filing marks the formal launch of Galapagos's new life as Lakefront Biotherapeutics: a lean, cash-rich "deal-making" biotech. Shareholders will vote to approve this transformation in April 2026. The success of this high-stakes bet now rests entirely on management's skill to deploy its €3 billion war chest to acquire the right drug programs.